CoChat

Effect of Valproate on Human Cerebral Glucose Metabolism

Leiderman, Deborah B., Balish, Marshall, Bromfield, Edward B., Theodore, William H. · 1991 · Epilepsia
Cited by 105

The DOI matches its Crossref record.

Abstract

Summary: We studied the effects of valproate (VPA) on local cerebral glucose metabolism (LCMRglc) in eight patients with partial seizure disorders and two with primary generalized epilepsy. Each patient had two positron‐emission tomography (PET) scans with 18 F‐2‐deoxyglucose (FDG), with, and without, VPA (mean level 52 mg/dl, range 30–127 mg/dl). Patients continued carbamazepine (CBZ) for both scans; serum concentrations were not significantly changed by VPA (CBZ range 5.4–12 mg/dl). Seven patients had the “without‐VPA” scan first. Mean interval between PET scans was 75 days. Global CMRglc was decreased by 22% by addition of VPA (7.2 ± 1.8 mg/100 g/min without VPA, 5.6 ± 1.1 g/min with VPA, p < 0.05, corrected). Thirteen regions of interest (ROIs) were analyzed in each hemisphere in each PET scan. Metabolic rates were significantly lower in 15 of 26 ROIs with VPA (p < 0.05, corrected). VPA depresses cerebral metabolism to a greater degree than do CBZ and phenytoin (PHT) but less than does phenobar‐bital (PB). The metabolic effect may be related to the mechanism of action and have neuropsychological implications. RÉSUMÉ: Les auteurs ont étudie l'effet du Valproate (VPA) sur le mélabolisme du glucose chez 8 patients présentant une épilepsie partielle et chez 2 patients présentant une épilepsie généralisée. Chaque patient a bénéficié de deux PET utilisant le 18‐F‐2‐déoxyglucose (FDG) avec ou sans VPA (taux moyen 52 mg/ dl, extrêmes 30–127 mg/dl). Les patients ont maintenu le traite‐ment par Carbamazépine (CBZ) pour les deux examens. Les taux sanguins ont été modifyés de façon significative par le VPA (taux de CBZ entre 5.4 et 12 mg/dl), 7 patients ont bénéficié du PET sans VPA d'abord. L'intervalle moyen éntre les 2 PET était de 75 jours. Le métabolisme global du glucose cérébral a été diminué de 22% par l'ajout de VPA (7.2 ± 1.8 mg/100 g/mn sans VPA, 5.6 ± 1.1 sous VPA, p < 0.5). Treize zones d'inteêet ont été analysées au niveau de chaque hémisphère pour chaque PET. Les taux métaboliques étaient significativement abaissés pour 15 des 26 zones sous VPA (p < 0.05). Le VPA déprime le méta‐bolisme cérébral de façon plus importante que la carbamazépine et la phénytoïne, mais moins que le phénobarbital. Cet effet métabolique peut être lié au mécanisme d'action et peut avoir des implications neuropsychologiques. RESUMEN: Se estudian los efectos de valproato (VPA) sobre el metabo‐lismo cerebral de la glucosa (LCMRglc) en 8 pacientes con ataques parciales y en 2 con epilepsyía generalizada primaria. Cada paciente fue estudiado con 2 PET utilizando la 18‐F‐2‐deoxiglucosa (FDG) con y sin VPA (niveles medios 52 mg/dl, rango: 30–127 mg/dl). Los pacientes continuaron tomando car‐bamacepina (CBZ) durante ambos estudios con PET. Las con‐centraciones séricas de la CBZ no cambiaron significativamente con el VPA (rango 5.4–12 mg/dl). Siete pacientes se estudiaron primero con el PET “sin VPA”. El intervalo promedio entre los PET fue de 75 dias. La CMRglc global se redujo en un 22% al anadir el VPA (7.2 ± 1.8 mg/100 g/min sin VPA, 5.6 ± 1.1 con VPA, p < 0.05, corregido). Se analizaron 13 regiones de interns (ROLs) en cada hemisferio y en cada estudio con PET. La ac‐tividad metabólica fue significativamente más baja en 15 de los 26 ROLs con VPA (p < 0.05, corregido). El VPA deprime el metabolismo cerebral en un mayor grado que lo hace la CBZ y la fenitoina pero menos que el fenobarbital. El efecto metabolico puede estar relacionado con los mecanismos de actión y tiene implicaciones neuropsicológicas. ZUSAMMENFASSUNG: Bei 8 Patienten mit Partial‐ und zwei Patienten mit generali‐sierter Epilepsie untersuchten wir den Einfluß von Valproat auf dem cerebralen Glucosestoffwechsel (LCMRgle). Jeder Patient wurde zweimal mit PET untersucht: Mit 18‐F‐2‐desoxyglucose (FDG) mit und ohne Valproat (mittlere Spiegel 52 mg/dl, 30–125 mg/dl). Während beider Untersuchungen wurde Carbamazepin kontinuierlich gegeben; die Serumspiegel wurden durch Zugabe von Valproat nicht signifikant verändert (CBZ 5.4–12 mg/dl). Bei 7 Patienten wurde das erste PET ohne Valproat durchgefiihrt. Mittleres Intervall der PET‐Untersuchungen 75 Tage. Die Ge‐samt‐CMRgle war um 22% erniedrigt nach Zugabe von VPA (7.2 ± 1.8 mg/lOOg/min und ohne VPA 5.6 ± 1.1 mit VPA, P 0.5). 13 Regionen wurden bei jedem PET in jeder Hemisphäre analysiert, Die Stoffwechselintensität war bei 15 von 26 Regionen unter VPA deutlich erniedrigt (p 0.05). VPA verminderte den cere‐bralen Metabolismus in einem größeren Ausmaß als CBZ odet PHT, aber weniger als Phenobarbital. Der metabolische Effekt konnte sich auf die Funktion auswirken und damit neuropsycho‐logische Bedeutung haben.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1157.1991.tb04671.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 105

Metadata

Authors
Leiderman, D. B., Balish, M., Bromfield, E. B., & Theodore, W. H.
Venue
Epilepsia
Publisher
Wiley
Published
1991-06
Volume
32
Issue
3
Pages
417-422
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2053114089
Cited by
105
References
0
FWCI
4.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Valproate on Human Cerebral Glucose Metabolism. https://app.cochat.ai/papers/10.1111/j.1528-1157.1991.tb04671.x
The paper
Leiderman, D. B., Balish, M., Bromfield, E. B., & Theodore, W. H. (1991). Effect of Valproate on Human Cerebral Glucose Metabolism. Epilepsia. https://doi.org/10.1111/j.1528-1157.1991.tb04671.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.